Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 1;23(6):45.
doi: 10.1007/s11926-021-01008-8.

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

Doruk Erkan  1 , Savino Sciascia  2 , Maria Laura Bertolaccini  3 , Hannah Cohen  4 ; APS ACTION Executive Committee
Collaborators, Affiliations
Review

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

Doruk Erkan et al. Curr Rheumatol Rep. .

Erratum in

Abstract

Purpose of review: APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)-positive patients. Given the expanding research activities of the network in the last decade since its creation, the purpose of this article is to review the scientific contributions of APS ACTION as well as future directions.

Recent findings: APS ACTION has achieved increased international collaboration with internal and external investigators for outcome, interventional, and mechanistic antiphospholipid syndrome (APS) studies. This has been linked to substantial progress in Core laboratory work, which has demonstrated that laboratories can achieve good agreement in performance of aPL assays by use of the same reagents, analyzer type, and protocols. APS ACTION will continue to identify gaps in the existing aPL/APS literature, design mechanistic studies to elucidate underlying mechanisms, and conduct prospective, large-scale clinical studies, all for the ultimate goal of early diagnosis and improved management of aPL-positive patients.

Keywords: APS ACTION; Antiphospholipid antibodies; Antiphospholipid syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4(2):295–306. doi: 10.1111/j.1538-7836.2006.01753.x. - DOI - PubMed
    1. Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin M. Antiphospholipid syndrome clinical research task force report. Lupus. 2011;20(2):219–224. - PubMed
    1. Erkan D, Lockshin MD, APS ACTION members APS ACTION-AntiPhospholipid Syndrome Alliance for clinical trials and international networking. Lupus. 2012;21(7):695–698. - PMC - PubMed
    1. Duarte-García A, Pham MM, Crowson CS, Amin S, Moder KG, Pruthi RK, Warrington KJ, Matteson EL. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheum. 2019;71(9):1545–1552. - PMC - PubMed
    1. Radin M, Sciascia S, Bazzan M, Bertero T, Carignola R, Montabone E, Montaruli B, Vaccarino A, Cecchi I, Rubini E, Roccatello D, Baldovino S, the Piedmont and Aosta Valley APS Consortium Antiphospholipid syndrome is still a rare disease-estimated prevalence in the Piedmont and Aosta Valley regions of Northwest Italy: comment on the article by Duarte-García et al. Arthritis Rheum. 2020;72(10):1774–1776. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources